Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $89.7143.
ESTA has been the subject of several research reports. Wall Street Zen cut Establishment Labs from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Citigroup upped their target price on shares of Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. BTIG Research reaffirmed a “buy” rating on shares of Establishment Labs in a research report on Monday. TD Cowen reaffirmed a “buy” rating on shares of Establishment Labs in a research report on Monday, June 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th.
Read Our Latest Report on ESTA
Establishment Labs Stock Down 1.5%
Establishment Labs (NASDAQ:ESTA – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The business had revenue of $59.88 million for the quarter, compared to the consensus estimate of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. Establishment Labs’s revenue for the quarter was up 44.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.70) EPS. Research analysts forecast that Establishment Labs will post -1.07 EPS for the current year.
Insider Transactions at Establishment Labs
In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of Establishment Labs stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the sale, the director directly owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. The trade was a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 255,000 shares of company stock valued at $18,144,896 over the last three months. Corporate insiders own 9.99% of the company’s stock.
Hedge Funds Weigh In On Establishment Labs
A number of hedge funds have recently modified their holdings of the stock. Assenagon Asset Management S.A. lifted its position in shares of Establishment Labs by 59.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 115,876 shares of the company’s stock worth $8,445,000 after purchasing an additional 43,164 shares in the last quarter. Bamco Inc. NY increased its holdings in shares of Establishment Labs by 30.2% in the third quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock valued at $48,443,000 after purchasing an additional 274,287 shares in the last quarter. Simplify Asset Management Inc. lifted its holdings in Establishment Labs by 92.1% during the 4th quarter. Simplify Asset Management Inc. now owns 72,894 shares of the company’s stock worth $5,313,000 after buying an additional 34,946 shares in the last quarter. Portolan Capital Management LLC boosted its position in Establishment Labs by 24.7% in the 3rd quarter. Portolan Capital Management LLC now owns 155,096 shares of the company’s stock valued at $6,357,000 after buying an additional 30,704 shares during the last quarter. Finally, Mudita Advisors LLP increased its stake in shares of Establishment Labs by 14.3% in the 3rd quarter. Mudita Advisors LLP now owns 686,764 shares of the company’s stock valued at $28,150,000 after buying an additional 86,100 shares during the period. 72.91% of the stock is owned by institutional investors and hedge funds.
Establishment Labs Company Profile
Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.
The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.
Read More
- Five stocks we like better than Establishment Labs
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.
